Preview

Российский офтальмологический журнал

Расширенный поиск

Афлиберцепт в лечении заболеваний сетчатки. Обзор клинических исследований

https://doi.org/10.21516/2072-0076-2017-10-2-103-111

Полный текст:

Аннотация

Афлиберцепт - гибридный белок - имитация рецептора VEGF, обладающий пролонгированной активностью. Описаны особенности строения молекулы афлиберцепта и его воздействие на патогенез заболеваний сетчатки. Приведены результаты клинических исследований по изучению эффективности и безопасности афлиберцепта при возрастной макулярной дегенерации (VIEW1, VIEW2), диабетическом макулярном отеке (VISTA, VIVID), макулярном отеке вследствие окклюзии центральной вены сетчатки (GALILEO, COPERNICUS) или ее ветвей (VIBRANT), а также при миопической хориоидальной неоваскуляризации (MYRROR) // Российский офтальмологический журнал, 2017; 2: 103-111.

Об авторах

Т. Д. Охоцимская
ФГБУ «Московский НИИ глазных болезней им. Гельмгольца» Минздрава России
Россия


О. В. Зайцева
ФГБУ «Московский НИИ глазных болезней им. Гельмгольца» Минздрава России
Россия


Список литературы

1. Ciulla T.A., Amador A.G., Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003; 26 (9): 2653-64.

2. Zechmeister-Koss I., Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br. J. Ophthalmol. 2012; 96 (2): 167-78.

3. Romero-Aroca. Current status in diabetic macular edema treatments. World J Diabetes. 2013; 4 (5): 165-9.

4. Resnikoff S., Pascolini D., Etya’ale D., et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82 (11): 844-51.

5. Congdon N., O’Colmain B., Klaver C.C., et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004; 122 (4): 477-85.

6. Rogers S., McIntosh R.L., Cheung N., et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117 (2): 313.e1-319.e1.

7. Wong T.Y., Ferreira A., Hughes R., et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am. J. Ophthalmol. 2014; 157: 9-25.

8. VEGF Trap-Eye (aflibercept ophthalmic solution) briefing document. Ophthalmologic Drugs Advisory Committee. June 17, 2011. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2011.

9. Rudge J.S., Holash J., Hylton D., et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl. Acad Sci USA. 2007; 104 (47): 18363-70.

10. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002; 99 (17): 11393-8.

11. Papadopoulos N., Martin J., Ruan Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15 (2): 171-85.

12. Manual for using the EYLEA® LP-003544 for medical purposes of January 20, 2017.

13. Li X., Lee C., Tang Z., et al. VEGF-B: a survival, or an angiogenic factor? Cell AdhMigr. 2009; 3 (4): 322-7.

14. Rakic J.M., Lambert V., Devy L., et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003; 44 (7): 3186-93.

15. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001; 7 (5): 575-83.

16. Stewart M.W., Rosenfield P.J. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 2008; 92 (5): 667-8.

17. Fauser S., Schwabecker V., Muether P.S. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am. J. Ophthalmol. 2014; 158 (3): 532-6.

18. Muether P.S., Hermann M.M., Dröge K., et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am. J. Ophthalmol. 2013; 156 (5): 989-93.

19. Muether P.S., Dröge K., Fauser S. Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab. Br. J. Ophthalmol. 2014; 98: 179-81.

20. Sarwar S., Bakbak B., Sadiq M.A., et al. Fusion Proteins: Aflibercept (VEGF Trap-Eye). Dev Ophthalmol. 2016; 55: 282-94.

21. Heier J.S., Brown D.M., Chong V., et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119 (12): 2537-48.

22. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.F., et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six week results of the VIEW studies. Ophthalmology. 2014; 121 (1): 193-201.

23. CATT Research Group. Martin D.F., Maguire M.G., Ying G.S. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2011; 364: 1897-908.

24. Martin D.F., Maguire M.G., Fine S.L., et al. Comparison of Age related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119: 1388-98.

25. Korobelnik J-F., Do D.V., Schmidt-Erfurth U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014; 121 (11): 2247-54.

26. Brown D.M., Schmidt-Erfurth U., Do D.V., et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015; 122 (10): 2044-52.

27. Heier J.S., Korobelnik J.F., Brown D.M., et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016 Nov.; 123 (11): 2376-85.

28. DRCRnet, Wells J.A., Glassman A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 2015; 372 (13): 1193-203.

29. Korobelnik J.F. Optimal Dose and Cost-effectiveness of Ranibizumab Treatment of Diabetic Macular Oedema. European Ophthalmic Review. 2016; 10 (2): 125-31.

30. Wells J.A., Glassman M.S., Avala A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trials. Ophthalmology. 2016; 123 (6): 1351-9.

31. Available at: http://www.peervoice.com/journal-club-decipheringlatest- data-improve-dme-treatment-choice.

32. Jampol L.M., Glassman A.R., Bressler N.M., et al. JAMA Ophthalmol. Published online October 6, 2016.

33. Boyer D., Heier J., Brown DM., et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012; 119 (5 May): 1024-32.

34. Holz F.G., Roider J., Ogura Y., et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br. J. Ophthalmol. 2013; 97 (3): 278-84.

35. Brown D.M., Heier J.S., Clark W.L., et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am. J. Ophthalmol. 2013; 155 (3): 429-37.

36. Korobelnik J.F., Holz F.G., Roider J., et al. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014; 121 (1): 202-8.

37. Heier J.S., Clark W.L., Boyer D.S., et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014; 121 (7): 1414-20.

38. Ogura Y., Roider J., Korobelnik J.F., et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am. J. Ophthalmol. 2014; 158 (5): 1032-8.

39. Campochiaro P.A., Clark W.L., Boyer D.S., et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015; 122 (3 Mar.): 538-44.

40. Clark W.L., Boyer D.S., Heier J.S., et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016; 123 (2 Feb.): 330-6.

41. Ikuno Y., Ohno-Matsui K., Wong T.Y., et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization. The MYRROR Study. Ophthalmology. 2015; 122: 1220-7.


Для цитирования:


Охоцимская Т.Д., Зайцева О.В. Афлиберцепт в лечении заболеваний сетчатки. Обзор клинических исследований. Российский офтальмологический журнал. 2017;10(2):103-111. https://doi.org/10.21516/2072-0076-2017-10-2-103-111

For citation:


Okhotsimskaya T.D., Zaitseva O.V. Aflibercept for the therapy of retinal diseases. A review of clinical studies. Russian Ophthalmological Journal. 2017;10(2):103-111. (In Russ.) https://doi.org/10.21516/2072-0076-2017-10-2-103-111

Просмотров: 69


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2072-0076 (Print)
ISSN 2587-5760 (Online)